- Boustead Securities
Thrive Testing & Biosafety With Its Virus Testing Technology Announces Regulation CF Offering
Irvine, CA, August 23, 2021 -- Thrive Testing & Biosafety, announces the commencement of its Regulation CF offering.
Thrive Testing and Biosafety, Inc. ("Thrive Biosafety"), the western U.S. licensee and an equity investor in the virus testing technology pioneered by Qanik DX, Toronto, Canada, is pleased to announce the launch of a Regulation CF, crowdfunding on FlashFunders, a FINRA member Funding Portal. A video explanation and demonstration of the testing technology, along with further detailed information, can be found at: flashfunders.com/thrivebiosafety
"After two successful seed rounds of financing, we are excited to partner with FlashFunders to build our shareholder base and add capital. This helps us prepare to launch the Qanik patented virus testing technology once it receives regulatory authorization," said Guy Zajonc, CEO. Zajonc added, "we intend to start with Covid-19, but the true potential of this testing technology is its ability to test for any known virus in a matter of seconds once our partners at Qanik DX have built the corresponding synthetic receptor for a known virus. We believe this is the future of virus testing.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $107,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $107,000, he/she is limited to investing 10% of the greater of the two amounts. For Accredited Investors, there are no restrictions on investing limits.
About Thrive Testing and Biosafety, Inc.
Thrive is a Delaware corporation, a licensee of and investor in Qanik DX, Toronto, Ontario, Canada. Thrive licensed 11 states of the western United States with an option to add the remainder of the U.S. to its license. Thrive is also a minority investor and equity unit holder in Qanik DX, and its virus testing capability is built around its patented Quantum Labeled Molecular Interaction (qMLI") technology. Additional information is available at www.thrivebiosafety.com.
About Sutter Securities Group, Inc.
Headquartered in Irvine, California, Sutter Securities Group, Inc. (“SSG”), founded in 2013, through its affiliates, is an innovator and investment banking solutions provider. SSG owns and operates Sutter Securities Clearing, LLC, and Sutter Securities, Inc, FINRA member broker-dealers; Sutter Shareholder Services, LLC, a SEC-registered transfer agent; FlashFunders Funding Portal, LLC, a FINRA member funding portal; and Sutter Capital Management, Inc. SSG, through its affiliates, operates a U.S.-based online securities platform whose underlying technology and regulatory infrastructure are designed to enable issuers to engage in Regulation D, Regulation A (known as Reg A+), Regulation S, Regulation CF and fully registered S-1 and F-1 Initial Public Offerings in compliance with applicable federal, state and non-U.S. securities laws. SSG is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. Additional information is available at www.flashfunders.com.
SEC Legend: Regulation CF Offerings Memoranda regarding the offerings for Thrive Biosafety described in this email will be filed with the Securities and Exchange Commission(“SEC”). The SEC typically will not review, and will not qualify, those memoranda. The SEC does not approve, pass upon the merits, or pass upon the accuracy or completeness of the information in such memoranda. You may obtain a copy of the memorandum for Thrive Biosafety here.
Liquidity Risk-Regulation CF Offerings Investment inThrive Biosafety have a high degree of risk including the lack of a market for their securities, as well as other risks common to Regulation CF investments generally, including, but not limited to, other substantial restrictions on transferability, making this investment highly illiquid.Thrive Biosafety can make no assurances about the success of their products, licensing or marketing efforts, any plans to make their securities liquid at any time, if ever, or their ability to eventually qualify for a listing on a national, or any other, securities exchange; consequently, investors in Thrive Biosafety may lose some or all of their investments.
We make statements herein that are considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend for these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement herein for purposes of complying with those safe harbor provisions. Similar statements are made in the Offering Circulars or offering memoranda of the companies mentioned herein. These forward-looking statements reflect, as applicable, our or mentioned companies’ current views about plans, intentions, expectations, strategies and prospects, which are based on the information currently available to them or us and on assumptions they or we have made. Although they or we believe that such plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, they or we can give no assurance that such plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond their or our control. For further discussion of the factors that could affect outcomes, please refer to the risk factors set forth in the “Risk Factors” sections of the Final Offering Circular of Regulation A+ Offerings or the memoranda of the Regulation D Offerings. They or we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.